110 related articles for article (PubMed ID: 18547991)
1. Glomerular disease related to anti-VEGF therapy.
Stokes MB; Erazo MC; D'Agati VD
Kidney Int; 2008 Dec; 74(11):1487-91. PubMed ID: 18547991
[No Abstract] [Full Text] [Related]
2. VEGF inhibition and renal thrombotic microangiopathy.
Eremina V; Jefferson JA; Kowalewska J; Hochster H; Haas M; Weisstuch J; Richardson C; Kopp JB; Kabir MG; Backx PH; Gerber HP; Ferrara N; Barisoni L; Alpers CE; Quaggin SE
N Engl J Med; 2008 Mar; 358(11):1129-36. PubMed ID: 18337603
[TBL] [Abstract][Full Text] [Related]
3. Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors.
Pellé G; Shweke N; Duong Van Huyen JP; Tricot L; Hessaïne S; Frémeaux-Bacchi V; Hiesse C; Delahousse M
Am J Kidney Dis; 2011 May; 57(5):756-9. PubMed ID: 21295897
[TBL] [Abstract][Full Text] [Related]
4. Acute renal failure in a patient receiving anti-VEGF therapy for advanced non-small cell lung cancer.
Zhao J; Li H; Wang M
J Thorac Oncol; 2009 Sep; 4(9):1185-7. PubMed ID: 19704343
[No Abstract] [Full Text] [Related]
5. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
6. Reversible posterior leukoencephalopathy syndrome and bevacizumab.
Glusker P; Recht L; Lane B
N Engl J Med; 2006 Mar; 354(9):980-2; discussion 980-2. PubMed ID: 16510760
[No Abstract] [Full Text] [Related]
7. Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.
Coltelli L; Allegrini G; Orlandi P; Giuntini N; Alì G; Fioravanti A; Bona E; Barletta MT; Fontanini G; Del Tacca M; Danesi R; Falcone A; Bocci G
Pharmacogenomics; 2009 Aug; 10(8):1225-9. PubMed ID: 19663667
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the jaw related to bevacizumab.
Estilo CL; Fornier M; Farooki A; Carlson D; Bohle G; Huryn JM
J Clin Oncol; 2008 Aug; 26(24):4037-8. PubMed ID: 18711196
[No Abstract] [Full Text] [Related]
9. Bevacizumab in the treatment of breast cancer.
Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
[TBL] [Abstract][Full Text] [Related]
10. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
11. [Bevacizumab-induced abdominal aortic thrombosis].
Védrine L; Chargari C
Presse Med; 2008 Dec; 37(12):1829-30. PubMed ID: 18829251
[No Abstract] [Full Text] [Related]
12. Bevacizumab in the treatment of metastatic breast cancer.
Traina TA
Oncology (Williston Park); 2009 Apr; 23(4):327-32. PubMed ID: 19476261
[TBL] [Abstract][Full Text] [Related]
13. [Anti-VEGF therapy with bevacizumab in breast cancer].
Tóth J; Gonda A; Szántó J
Lege Artis Med; 2008 Oct; 18(10):669-73. PubMed ID: 19227609
[TBL] [Abstract][Full Text] [Related]
14. Reversible posterior leukoencephalopathy syndrome and bevacizumab.
Ozcan C; Wong SJ; Hari P
N Engl J Med; 2006 Mar; 354(9):980-2; discussion 980-2. PubMed ID: 16514715
[No Abstract] [Full Text] [Related]
15. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Marty M; Pivot X
Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
[TBL] [Abstract][Full Text] [Related]
16. Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration.
Stylianou K; Lioudaki E; Papadimitraki E; Kokologiannakis G; Kroustalakis N; Liotsi C; Giannakakis K; Georgoulias V; Daphnis E
Nephrol Dial Transplant; 2011 May; 26(5):1742-5. PubMed ID: 21382992
[TBL] [Abstract][Full Text] [Related]
17. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.
Burstein HJ; Chen YH; Parker LM; Savoie J; Younger J; Kuter I; Ryan PD; Garber JE; Chen H; Campos SM; Shulman LN; Harris LN; Gelman R; Winer EP
Clin Cancer Res; 2008 Dec; 14(23):7871-7. PubMed ID: 19047116
[TBL] [Abstract][Full Text] [Related]
18. High protein-induced glomerular hypertrophy is vascular endothelial growth factor-dependent.
Schrijvers BF; Rasch R; Tilton RG; Flyvbjerg A
Kidney Int; 2002 May; 61(5):1600-4. PubMed ID: 11967009
[TBL] [Abstract][Full Text] [Related]
19. Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer.
Farhat MH; El-Saghir NS; Shamseddine AI
Breast; 2009 Feb; 18(1):66-8. PubMed ID: 19013064
[TBL] [Abstract][Full Text] [Related]
20. Papulopustular eruption after intravitreal bevacizumab (Avastin).
Amselem L; Diaz-Llopis M; Garcia-Delpech S; Montero J; Palomares P; Cervera E
Acta Ophthalmol; 2009 Feb; 87(1):110-1. PubMed ID: 18577190
[No Abstract] [Full Text] [Related]
[Next] [New Search]
